Ocular complications associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) – Clinical evidence and insights
Indian Journal of Ophthalmology · 2026-07 · 74 (7) · 974-981
DOI: 10.4103/ijo.ijo_2659_25 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Indian Journal of Ophthalmology, online erschienen am 12.03.2026. Verfasst von Naina Mohamed Pakkir Maideen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Mohammed Bin Rashid University of Medicine and Health Sciences, College of Medicine, Dubai, UAE. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Optic Neuropathy, Ischemic. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Type 2 diabetes mellitus (T2DM) and obesity are commonly treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs). However, there have been growing concerns over the possibility that these medications may result in ocular adverse events, such as nonarteritic anterior ischemic optic neuropathy (NAION). Standard clinical care can overlook these potentially fatal adverse effects. The purpose of this review was to compile the most recent data on ocular side effects associated with GLP-1 RA therapy, assess their clinical relevance, and highlight necessary preventative and monitoring measures. A thorough search of the literature was conducted using Medline/PubMed/PMC, Google Scholar, Scopus, Web of Science, and ScienceDirect. Relevant literature, including observational studies, randomized trials, case reports, and pharmacovigilance data, was selected for its discussion of GLP-1 RAs and associated eye-related adverse events. Semaglutide, a GLP-1 RA, has been associated in a number of studies and safety assessments with an increased risk of NAION and the progression of diabetic retinopathy, especially in patients with underlying eye disorders. Findings, however, were mixed because no statistically significant link was found in a number of cohort studies and meta-analyses. The necessity for additional research was supported by data from adverse event reporting systems that showed disproportionality signals. Clinicians should be mindful of the potential ocular hazards associated with GLP-1 RAs, even though these medications remain useful in treating T2DM and obesity. Closer ophthalmologic monitoring may be beneficial for patients with known diabetic eye problems. Further prospective research with well-defined ocular outcomes is required to elucidate these correlations and guarantee the secure administration of GLP-1 RAs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mohammed Bin Rashid University of Medicine and Health Sciences, College of Medicine, Dubai, UAE.
- Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Department of Pharmacology, Chennai, Tamil Nadu, India.
- Faculty of Pharmacy, Karpagam Academy of Higher Education, Coimbatore, Tamil Nadu, India.
- Department of Pharmacy Practice, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia.
Zitieren
APA
Maideen, N. M. P., Al Rashid, S., Balasubramanian, R., & Amirthalingam, P. (2026). Ocular complications associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) – Clinical evidence and insights. Indian Journal of Ophthalmology, 74(7), 974-981. https://doi.org/10.4103/ijo.ijo_2659_25
Vancouver
Maideen NMP, Al Rashid S, Balasubramanian R, Amirthalingam P. Ocular complications associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) – Clinical evidence and insights. Indian Journal of Ophthalmology. 2026;74(7):974-981. doi:10.4103/ijo.ijo_2659_25
BibTeX
@article{Maideen2026,
author = {Maideen, Naina Mohamed Pakkir and Al Rashid, Sulthan and Balasubramanian, Rajkapoor and Amirthalingam, Palanisamy},
title = {Ocular complications associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) – Clinical evidence and insights},
journal = {Indian Journal of Ophthalmology},
year = {2026},
volume = {74},
number = {7},
pages = {974--981},
doi = {10.4103/ijo.ijo_2659_25}
}
EUVIMED